Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesBusiness Wire • 09/21/23
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer ConferenceProactive Investors • 08/14/23
Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceBusiness Wire • 08/14/23
Biocept appoints Antonino Morales as president and chief executive officerProactive Investors • 06/21/23
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023Business Wire • 06/14/23
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastasesProactive Investors • 06/05/23
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus CytologyBusiness Wire • 06/05/23
Biocept ends 1Q with $6.8M cash; 'exceptionally pleased' with FORESEE clinical trial progressProactive Investors • 05/11/23
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial yearProactive Investors • 04/17/23
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastasesProactive Investors • 03/24/23
Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal MetastasesBusiness Wire • 03/24/23